Safinamide

Description: Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098µM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8µM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy. Target: MAO. Smiles: O(CC1=CC(F)=CC=C1)C2=CC=C(CN[C@H](C(N)=O)C)C=C2. References: Stocchi F, Torti M. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Drug Des Devel Ther. 2016 Feb 5,10:609-18.